Investor Relations |
Our primary goal is to provide products that help improve the lives of patients with rare CNS and inflammatory diseases and disorders, and by doing this successfully we will build long term value for our shareholders.
Recent Releases
Mar 1, 2010
Questcor Reports Solid Fourth Quarter Results
Feb 11, 2010
Questcor Announces Fourth Quarter 2009 Earnings Release Date and Conference Call
Feb 4, 2010
Questcor Appoints Jason Zielonka, M.D. Chief Medical Officer
Events & Presentations
Details on upcoming events are not yet available.
| Stock Chart | |
|---|---|
|
|
|
| Stock Quote | |
| Questcor Pharmaceuticals, Inc. | |
| Price: | 6.75 |
| Change: | - 0.16 |
| Day High: | 6.99 |
| Day Low: | 6.55 |
| Volume: | 896,100 |
| Delayed at least 20 minutes. Provided by eSignal. |
|
Transfer Agent
Computershare Trust Co., Inc.Phone 303-262-0600
Corporate Counsel
Stradling Yocca Carlson & RauthNewport Beach, CA
Independent Accountants
Odenberg Ullakko Muranishi & Co. LLPSan Francisco, CA
Investor Relations Contacts
Phone 510-400-0700or
Doug Sherk, EVC Group, 415-896-6820



